Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351221 · ClinicalTrials.gov registry record · Phase 2
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
A Phase 2 study, sponsored by Insmed Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00351221 is a Phase 2 study that was terminated before completion, run by Insmed Incorporated. The registered enrollment target is 24 participants.
The verdict
NCT00351221, a Phase 2 study, was terminated before completion, sponsored by Insmed Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested as a possible cause of short stature seen in Noonan syndrome children. Administration of our investigational product is intended to bypass the abnormalities in the GH-IGF axis, and hopefully improve body growth.
Interventions
- DRUG rhIGF-1/rhIGFBP-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351221
The ClinicalTrials.gov registry entry for NCT00351221 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhIGF-1/rhIGFBP-3 is the first listed.
NCT00351221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351221 about?
NCT00351221 is a clinical study titled "Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome". The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested as a possible cause of short stature seen in Noonan syndrome children. A...
What is the current status of trial NCT00351221?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants.
What interventions are being tested in trial NCT00351221?
The interventions under investigation include: rhIGF-1/rhIGFBP-3 (DRUG).
Who is sponsoring clinical trial NCT00351221?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.